Cure Vac's oncology portfolio
GPTKB entity
Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:aims_to |
improve patient outcomes
|
| gptkbp:based_on |
m RNA technology
|
| gptkbp:collaborated_with |
research institutions
|
| gptkbp:developer |
combination therapies
therapeutic vaccines |
| gptkbp:focuses_on |
gptkb:healthcare_organization
targeted therapies |
| https://www.w3.org/2000/01/rdf-schema#label |
Cure Vac's oncology portfolio
|
| gptkbp:includes |
personalized cancer vaccines
m RNA therapies |
| gptkbp:is_aimed_at |
reduce cancer mortality
various cancer types |
| gptkbp:is_designed_to |
activate immune response
|
| gptkbp:is_evaluated_by |
safety and efficacy
clinical studies |
| gptkbp:is_expected_to |
enhance therapeutic outcomes
advance cancer immunotherapy drive innovation in oncology. provide new treatment options |
| gptkbp:is_incorporated_in |
biomarker research
|
| gptkbp:is_part_of |
Cure Vac's overall strategy
|
| gptkbp:is_supported_by |
gptkb:Research_Institute
|
| gptkbp:receives_funding_from |
data analytics
|
| gptkbp:targets |
solid tumors
|
| gptkbp:utilizes |
immune modulation
advanced delivery systems |
| gptkbp:bfsParent |
gptkb:Cure_Vac's_m_RNA_vaccine_for_bladder_cancer
|
| gptkbp:bfsLayer |
5
|